CD8A and colorectal cancer: Further, we demonstrated that the percentage of TOX and their MFI values were significantly downregulated in the DAC, DOX, and 5-FU treatment groups compared with the PBS control group in the CT26 colorectal cancer model (Figures 3A, B), with a higher proportion of TCF-1+TOX-CD8+ TTSM and lower proportion of TCF-1+TOX+CD8+ Tpex cells (Figures 3C, D).